Toward the development of podocyte-specific drugs

Slides:



Advertisements
Similar presentations
Takehiko Wada, Jeffrey W. Pippin, Yoshio Terada, Stuart J. Shankland 
Advertisements

Volume 79, Issue 11, Pages (June 2011)
F. Guan, G. Villegas, J. Teichman, P. Mundel, A. Tufro 
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria  Dan Wang, Chunsun Dai, Yingjian Li, Youhua.
Volume 66, Issue 1, Pages (July 2004)
Volume 134, Issue 7, Pages (June 2008)
Regulation of mesangial cell proliferation
NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a non-canonical manner  Hans-Joachim Anders, Maciej.
Volume 85, Issue 4, Pages (April 2014)
Volume 56, Issue 4, Pages (October 1999)
Volume 78, Issue 4, Pages (August 2010)
Volume 77, Issue 11, Pages (June 2010)
Volume 55, Issue 5, Pages (May 1999)
Volume 73, Issue 5, Pages (March 2008)
Volume 76, Issue 1, Pages (July 2009)
Volume 72, Issue 4, Pages (August 2007)
Exosomes/microvesicles as a mechanism of cell-to-cell communication
Volume 4, Issue 1, Pages (July 2001)
Volume 68, Issue 6, Pages (December 2005)
Difucosylated oligosaccharide Lewis Y is contained within integrin αvβ3 on RL95-2 cells and required for endometrial receptivity  Dongmei Zhang, Ph.D.,
Volume 93, Issue 4, Pages (April 2018)
Volume 55, Issue 5, Pages (May 1999)
Proteomic analysis of the slit diaphragm complex: CLIC5 is a protein critical for podocyte morphology and function  Brian A. Pierchala, Maura R. Muñoz,
Peter J. Nelson, Thomas O. Daniel  Kidney International 
Volume 84, Issue 5, Pages (November 2013)
Manuela Schmidt, Danny Gutknecht, Jan C
Mechanisms of the proteinuria induced by Rho GTPases
Proteinuria: an enzymatic disease of the podocyte?
Volume 83, Issue 6, Pages (June 2013)
Volume 77, Issue 11, Pages (June 2010)
Figure 4 Podocyte–endothelial cross talk and activation of heparanase
Akio Horiguchi, Mototsugu Oya, Ken Marumo, Masaru Murai 
Volume 93, Issue 3, Pages (March 2018)
Glomerular filtration: the charge debate charges ahead
Volume 14, Issue 1, Pages (January 2004)
Volume 74, Issue 5, Pages (September 2008)
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
Hsin-Hui Wang, Tzong-Yann Lee, Ching-Yuang Lin  Kidney International 
Personalized Medicine: Patient-Predictive Panel Power
Volume 74, Issue 10, Pages (November 2008)
Volume 79, Issue 9, Pages (May 2011)
Liming Wang, Jae-Hyung Chang, Anne F. Buckley, Robert F. Spurney 
Punit Yadav, Nelson Leung, Paul W. Sanders, Paul Cockwell 
Toward the development of podocyte-specific drugs
Anemia management and chronic renal failure progression
BMP-7 protects mesangial cells from injury by polymeric IgA
Volume 79, Issue 4, Pages (February 2011)
Volume 21, Issue 11, Pages (November 2014)
Podocytes in culture: past, present, and future
Volume 82, Issue 3, Pages (August 2012)
Volume 68, Issue 2, Pages (August 2005)
Nck Links Nephrin to Actin in Kidney Podocytes
Flora Ambre Honoré, Vincent Méjean, Olivier Genest  Cell Reports 
Old friends form alliance against podocytes
EMT and proteinuria as progression factors
Volume 67, Issue 2, Pages (February 2005)
Advances in the pathogenesis of HIV-associated kidney diseases
Volume 21, Issue 1, Pages (January 2013)
Volume 73, Issue 9, Pages (May 2008)
Volume 68, Issue 6, Pages (December 2005)
Design of allele-specific inhibitors to probe protein kinase signaling
Volume 73, Issue 8, Pages (April 2008)
What's a CLIC doing in the podocyte?
Another niche for Notch
Novel aspects of complement in kidney injury
Volume 68, Issue 1, Pages (July 2005)
Volume 11, Issue 13, Pages (July 2001)
What is myeloperoxidase doing in ANCA-associated glomerulonephritis?
Podocyte GTPases regulate kidney filter dynamics
Emmanuel Vial, Erik Sahai, Christopher J. Marshall  Cancer Cell 
Presentation transcript:

Toward the development of podocyte-specific drugs Jochen Reiser, Vineet Gupta, Andreas D. Kistler  Kidney International  Volume 77, Issue 8, Pages 662-668 (April 2010) DOI: 10.1038/ki.2009.559 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Pathways involved in acquired glomerular diseases representing targets for podocyte-specific drugs. A schematic cross-section of a podocyte foot process with the corresponding cell body, the glomerular basement membrane, and the glomerular endothelium is shown. Pathways involved in podocyte injury that may be drug-targeted are depicted in different colors. Sustaining nephrin expression and phosphorylation (yellow) might contribute to both antiapoptotic signaling and actin polymerization. The B7-1 pathway (light blue) may be targeted by (1) toll-like receptor-4 antagonists or (2) blocking the binding of B7-1 to slit diaphragm structure proteins. Urokinase plasminogen-activator receptor (uPAR)-induced podocyte motility (violet) could be inhibited by (1) interfering with binding of uPAR to αvβ3 integrin, (2) inhibiting β3 integrin activation, or (3) inhibiting binding of αvβ3 integrin to vitronectin. The notch pathway (dark blue) can be targeted by (1) interfering with its upstream activation by blocking the TGF-β1 effect, (2) inhibiting γ-secretase, which is required for proteolytic receptor activation, or (3) interfering with target gene transcription. TRPC6 channels (red) may be targeted by (1) channel blockers or (2) inhibiting their expression. The CatL pathway (green) could be targeted by (1) specifically inhibiting CatL expression or activity, (2) shifting the equilibrium of synaptopodin toward the phosphorylated form by inhibiting calcineurin-mediated dephosphorylation or enhancing PKA or CAMKII-mediated phosphorylation, (3) protecting synaptopodin and dynamin by compounds that bind to the CatL cleavage site, or (4) delivering cleavage-resistant synaptopodin or dynamin mutants. Kidney International 2010 77, 662-668DOI: (10.1038/ki.2009.559) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 2 Phenotypic podocyte assays used for high-content screening (HCS). Cultured podocytes can be used in HCS assays for automated detection of cellular morphology and stress fiber formation in a high-throughput environment. (a) An HCS captured image from a well of a 96-well plate with podocytes stained with phalloidin to detect actin-stress fibers. (b) Same image as in panel a stained with Cell Mask Blue (to stain cell nuclei and cytoplasm). (c) An overlay of images in panels a and b. (d) An overlay of automatically calculated cellular boundaries that can be used in measuring various cellular characteristics (such as cell number, cell size, and intensity of stress fibers per cell) on the raw image (a) from the 96-well plate. Kidney International 2010 77, 662-668DOI: (10.1038/ki.2009.559) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 3 Schematic of a workflow for a primary drug screen with cultured podocytes. Cultured podocytes are grown under permissive conditions at 33°C to allow for proliferation. Next, cells are transferred to 96-well HTS microtiter plates and allowed to differentiate under nonpermissive conditions at 37°C. Fully differentiated podocytes are incubated with chemical compound libraries, and the effect of compounds on cells is measured using a variety of cell-based readout assays. These detection assays include high-content imaging to detect changes in cellular phenotypes, measurement of homogenous changes in absorbance, fluorescence- or luminescence-based gene reporter assays as well as determination of changes in cell viability and cellular function, such as adhesion and motility. Kidney International 2010 77, 662-668DOI: (10.1038/ki.2009.559) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 4 Cyclo-RGDfV as an example of a small molecule targeting podocytes. (a) Chemical structure of the anti-integrin αvβ3 drug cyclo-RGDfV. (b) Three-dimensional crystal structure of the extracellular domains of integrin αvβ3 (shown as a ribbon model with αv-chain in blue and β3-chain in red) bound to cyclo-RGDfV (green, shown as a CPK model). Bound metal ions are shown as gray spheres. Models a and b are based on the study by Dechantsreiter et al.44 and Xiong et al.,45 respectively. Cyclo-RGDfV has been successfully used to treat proteinuria in the lipopolysaccharide-mouse model.10 Kidney International 2010 77, 662-668DOI: (10.1038/ki.2009.559) Copyright © 2010 International Society of Nephrology Terms and Conditions